pharmaphorum October 25, 2024
Phil Taylor

MSD has acquired Yale University spinout Modifi Biosciences, claiming ownership of a potential new class of therapeutics for difficult-to-treat brain tumours, including glioblastomas.

Under the terms of the deal, MSD (known as Merck & Co in the US and Canada) is paying $30 million upfront for Modifi, with up to $1.4 billion in milestone payments tied to the development of its drug candidates, which target cancer cells lacking expression of a DNA repair protein called O6-methylguanine methyl transferase (MGMT).

Approximately half of glioblastomas and more than two-thirds of grade II and III glioma tumours are deficient in MGMT.

Modifi was only formed in 2021 and its drug candidates are still in preclinical development, but the science behind them has been...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
Related Articles:
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
GLP-1 drug coverage for obesity making inroads with large employers: Mercer

Share This Article